Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.50 |
| ▸ | CPB1 | P15086 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3685448 | 1.00 | CPB2 (0.50) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL10009250 | 0.96 | CPB2 (0.52) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL10009247 | 0.96 | CPB2 (0.52) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL19138219 | 0.95 | CPB2 (0.51) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL5964368 | 0.95 | CPB2 (0.51) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL29503862 | 0.95 | CPB2 (0.51) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1667030 | 0.95 | CPB2 (0.51) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL19138220 | 0.95 | CPB2 (0.51) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1667027 | 0.95 | CPB2 (0.51) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL30978072 | 0.95 | CPB2 (0.51) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6410680-B1 | STRESS RESISTANCE THERAPY | DENDRIMOLECULAR, INC. | 2002-06-25 | — | — | US | claimed |
| CN-115368344-A | Histidine derivative and preparation method and application thereof | 湖北科技学院 | 2022-11-22 | — | — | CN | disclosed |
| CN-107108520-B | Process for the synthesis of ergothioneine and related compounds | 开普敦大学 | 2018-11-02 | — | — | CN | disclosed |
| US-7812044-B2 | Anticancer agents | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-12 | — | — | US | disclosed |
| US-20050119323-A1 | Anticancer agents | UEMURA, HIROJI (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1444988-A1 | ANTICANCER AGENTS | Takeda Chemical Industries, Ltd. (JP) | 2004-08-11 | — | — | EP | disclosed |
| EP-0799221-B1 | QUINAZOLINES AS INHIBITORS OF ENDOTHELIN CONVERTING ENZYME | WARNER LAMBERT CO (US) | 2002-10-30 | — | — | EP | disclosed |
| US-5614510-A | AMMONIUM SALTS | PERSTORP AB (SE) | 1997-03-25 | — | — | US | disclosed |
| EP-0627922-A1 | A PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY OF INOSITOL PHOSPHATE | PERSTORP AB (SE) | 1994-12-14 | — | — | EP | disclosed |
| WO-1994028012-A1 | HYDROXAMATE INHIBITORS OF ENDOTHELIN CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1993016705-A1 | A PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY OF INOSITOL PHOSPHATE | PERSTORP AB (SE) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119323-A1 | Anticancer agents | AGT, ACE, CCAR2 | CPB2 711/4885CPB1 976/4885ALDH1A1 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.